1.Tumescent Local Anesthesia for Hand Surgery: Improved Results, Cost Effectiveness, and Wide-Awake Patient Satisfaction.
Donald LALONDE ; Alison MARTIN
Archives of Plastic Surgery 2014;41(4):312-316
This is a review article of the wide-awake approach to hand surgery. More than 95% of all hand surgery can now be performed without a tourniquet. Epinephrine is injected with lidocaine for hemostasis and anesthesia instead of a tourniquet and sedation. This is sedation-free surgery, much like a visit to a dental office. The myth of danger of using epinephrine in the finger is reviewed. The wide awake technique is greatly improving results in tendon repair, tenolysis, and tendon transfer. Here, we will explain its advantages.
Anesthesia
;
Anesthesia, Local*
;
Cost-Benefit Analysis*
;
Dental Offices
;
Epinephrine
;
Fingers
;
Hand*
;
Hemostasis
;
Lidocaine
;
Patient Satisfaction*
;
Tendon Transfer
;
Tendons
;
Tourniquets
2.Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study.
Prunella BLINMAN ; Corona GAINFORD ; Mark DONOGHOE ; Julie MARTYN ; Penny BLOMFIELD ; Peter GRANT ; Ganessan KICHENADASSE ; Michelle VAUGHAN ; Alison BRAND ; Catherine SHANNON ; Val GEBSKI ; Martin STOCKLER ; Michael FRIEDLANDER
Journal of Gynecologic Oncology 2013;24(4):359-366
OBJECTIVE: Intraperitoneal (IP) chemotherapy in women with optimally debulked stage III ovarian cancer has been reported to prolong overall survival, but has not been widely adopted due to concerns about its toxicity, inconvenience and acceptability to patients. The purposes of this study were to determine the regimen's feasibility, adverse events, catheter-related complications, progression-free survival, health-related quality of life (HRQL), and patients' preferences for IP versus intravenous (IV) chemotherapy. METHODS: We conducted a single arm, multi-center study of IP chemotherapy with IV paclitaxel 135 mg/m2 (D1) over 3 hours, IP cisplatin 75 mg/m2 (D2), and IP paclitaxel 60 mg/m2 (D8) for 6 cycles in women with optimally debulked stage III ovarian or related cancers. RESULTS: Thirty-eight eligible patients were recruited from 12 sites between July 2007 and December 2009. Seventy-one percent (n=27) completed at least 4 cycles and 63% (n=24) completed all 6 cycles. Grade 3 or 4 adverse events included nausea (n=2), vomiting (n=2), abdominal pain (n=2), and diarrhea (n=1), but not febrile neutropenia, neurotoxicity, or nephropathy. There were no treatment-related deaths. Catheter-related complications were the most frequent cause of early discontinuation of treatment (16 patients, 21%). Apart from neurotoxicity HRQL which worsened over time, HRQL was stable or improved with time. Most patients (> or =50%) judged moderate benefits (e.g., an extra 6 months survival time or a 5% improvement in survival rates) necessary to make IP chemotherapy worthwhile. CONCLUSION: IP chemotherapy was feasible, tolerable, and most participants considered moderate survival benefits sufficient to warrant the adverse effects and inconvenience.
Abdominal Pain
;
Arm
;
Cisplatin
;
Diarrhea
;
Disease-Free Survival
;
Female
;
Humans
;
Infusions, Parenteral
;
Nausea
;
Neutropenia
;
Ovarian Neoplasms
;
Paclitaxel
;
Quality of Life
;
Vomiting